Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.69 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13331622 | 1.00 | CYP3A4 (0.69) | CYP3A4SLC7A5NLNMEN1ALDH1A1 | |
| SCHEMBL18162790 | 1.00 | CYP3A4 (0.69) | CYP3A4SLC7A5NLNMEN1ALDH1A1 | |
| SCHEMBL27946609 | 0.87 | CYP3A4 (0.69) | CYP3A4SLC7A5NLN | |
| SCHEMBL12259752 | 0.86 | CYP3A4 (0.63) | CYP3A4SLC7A5NLN | |
| SCHEMBL19227330 | 0.86 | CYP3A4 (0.63) | CYP3A4SLC7A5NLN | |
| SCHEMBL27450330 | 0.86 | CYP3A4 (0.67) | CYP3A4SLC7A5NLN | |
| SCHEMBL12234246 | 0.85 | CYP3A4 (0.61) | CYP3A4SLC7A5NLN | |
| SCHEMBL27913326 | 0.84 | CYP3A4 (0.69) | CYP3A4SLC7A5NLN | |
| SCHEMBL27802167 | 0.84 | CYP3A4 (0.64) | CYP3A4SLC7A5NLN | |
| SCHEMBL24712703 | 0.83 | NLN (0.61) | NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5409893-A | Administering with platinum complexes | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2016055610-A1 | STABLE GLP-1 BASED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS | NOVO NORDISK A/S (DK) | 2016-04-14 | — | — | WO | disclosed |
| WO-2015185640-A1 | GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | NOVO NORDISK A/S (DK) | 2015-12-10 | — | — | WO | disclosed |
| EP-2932981-A2 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK A/S (DK) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014170496-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | NOVO NORDISK A/S (DK) | 2014-10-23 | — | — | WO | disclosed |
| EP-0757677-B1 | BENZOCYCLOHEXYLIMIDAZOLETHIONE DERIVATIVES | SYNTEX LLC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| US-5409893-A | Administering with platinum complexes | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-04-25 | — | — | US | disclosed |
| EP-0471709-B1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA (IT) | 1994-11-30 | — | — | EP | disclosed |
| EP-0471709-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS. | BOEHRINGER MANNHEIM ITALIA (IT) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990013553-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CYP3A4 4537/4885SLC7A5 1484/4885NLN 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.